Compare FUBO & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUBO | VIR |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.2M | 1.0B |
| IPO Year | 2020 | 2019 |
| Metric | FUBO | VIR |
|---|---|---|
| Price | $1.34 | $7.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $3.98 | ★ $28.63 |
| AVG Volume (30 Days) | ★ 19.1M | 1.8M |
| Earning Date | 02-03-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,855,678,000.00 | $16,860,000.00 |
| Revenue This Year | $10.74 | N/A |
| Revenue Next Year | $10.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.60 | N/A |
| 52 Week Low | $1.31 | $4.16 |
| 52 Week High | $4.72 | $10.01 |
| Indicator | FUBO | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 15.09 | 56.91 |
| Support Level | $1.31 | $7.08 |
| Resistance Level | $1.61 | $7.89 |
| Average True Range (ATR) | 0.14 | 0.47 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 3.54 | 61.32 |
FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.